Meeting
2015 ASCO Annual Meeting
A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).
Authors
Dan Paul Zandberg
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD
Dan Paul Zandberg , Anthony Jarkowski III, Ugochi A Emeribe , Trishna Goswami , Giovanni Melillo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT02207530
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS6086)
DOI
10.1200/jco.2015.33.15_suppl.tps6086
Abstract #
TPS6086
Poster Bd #
408b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.
First Author: Steven Francis Powell
Poster
2023 ASCO Annual Meeting
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
First Author: Ezra E.W. Cohen
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs